businesspress24.com - Insys Therapeutics to Report Third Quarter 2013 Financial Results on November 12
 

Insys Therapeutics to Report Third Quarter 2013 Financial Results on November 12

ID: 1276939

(firmenpresse) - PHOENIX, AZ -- (Marketwired) -- 10/29/13 -- Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced that the Company will release its financial results for the third quarter of 2013 on Tuesday, November 12, 2013, before the U.S. financial markets open.

Following the release of the financial results, Michael L. Babich, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 11:00 a.m. Eastern Standard Time.

Interested parties may participate in the conference call by dialing 888-329-8893 (U.S.) or 719-325-2244 (International), 5-10 minutes prior to the start of the call. A replay will be available shortly after the completion of the call for two weeks by dialing 888-203-1112 (U.S.) or 719-457-0820 (International) and entering conference call ID number 5992606. A live audio webcast and archive of the call will also be available at .

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.



Darryl S. Baker
Chief Financial Officer
Insys Therapeutics, Inc.
602-910-2617

Lisa M. Wilson
President
In-Site Communications, Inc.
212-452-2793






Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Theravance Reports Third Quarter 2013 Financial Results
Horizon Pharma Presents New Clinical Data Demonstrating RAYOS(R) (Prednisone) Delayed-Release Tablets Produce a Sustained Reduction in Morning Symptoms in Patients With Rheumatoid Arthritis
Bereitgestellt von Benutzer: Marketwired
Datum: 29.10.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 1276939
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

PHOENIX, AZ


Phone:

Kategorie:

Drugs


Anmerkungen:


Diese Pressemitteilung wurde bisher 109 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Insys Therapeutics to Report Third Quarter 2013 Financial Results on November 12
"
steht unter der journalistisch-redaktionellen Verantwortung von

Insys Therapeutics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Insys Therapeutics



 

Who is online

All members: 10 564
Register today: 1
Register yesterday: 0
Members online: 0
Guests online: 88


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.